ConductScience.org, home
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
API referenceFor AI assistants

Trial · NCT00153101

Adverse events12,525

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 12,525Pages stop at row 10,000

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
seriousAgranulocytosisBlood and lymphatic system disordersTelmisartan/Ramipril (ONTARGET)08,502
seriousAgranulocytosisBlood and lymphatic system disordersTelmisartan (ONTARGET)18,542
seriousAgranulocytosisBlood and lymphatic system disordersRamipril (ONTARGET)08,576
seriousAgranulocytosisBlood and lymphatic system disordersTelmisartan (TRANSCEND)02,954
seriousAgranulocytosisBlood and lymphatic system disordersPlacebo (TRANSCEND)02,972
seriousAnaemiaBlood and lymphatic system disordersTelmisartan/Ramipril (ONTARGET)1258,502
seriousAnaemiaBlood and lymphatic system disordersTelmisartan (ONTARGET)1568,542
seriousAnaemiaBlood and lymphatic system disordersRamipril (ONTARGET)1318,576
seriousAnaemiaBlood and lymphatic system disordersTelmisartan (TRANSCEND)432,954
seriousAnaemiaBlood and lymphatic system disordersPlacebo (TRANSCEND)362,972
seriousAnaemia haemolytic autoimmuneBlood and lymphatic system disordersTelmisartan/Ramipril (ONTARGET)08,502
seriousAnaemia haemolytic autoimmuneBlood and lymphatic system disordersTelmisartan (ONTARGET)18,542
seriousAnaemia haemolytic autoimmuneBlood and lymphatic system disordersRamipril (ONTARGET)08,576
seriousAnaemia haemolytic autoimmuneBlood and lymphatic system disordersTelmisartan (TRANSCEND)02,954
seriousAnaemia haemolytic autoimmuneBlood and lymphatic system disordersPlacebo (TRANSCEND)02,972
seriousAnaemia macrocyticBlood and lymphatic system disordersTelmisartan/Ramipril (ONTARGET)28,502
seriousAnaemia macrocyticBlood and lymphatic system disordersTelmisartan (ONTARGET)08,542
seriousAnaemia macrocyticBlood and lymphatic system disordersRamipril (ONTARGET)18,576
seriousAnaemia macrocyticBlood and lymphatic system disordersTelmisartan (TRANSCEND)02,954
seriousAnaemia macrocyticBlood and lymphatic system disordersPlacebo (TRANSCEND)02,972

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00153101/events

API referenceFor AI assistants